🧾 What This Document Is

This is an 8-K filing, which is a report companies file with the SEC to announce major events that shareholders should know about. Attached is the full Securities Purchase Agreement (EX-10.1), the contract detailing a private fundraising deal.

In simple terms: Artelo Biosciences just signed a deal to sell about $11 million worth of new stock and warrants to a group of investors. This is a common way for smaller, development-stage companies to raise cash.

💰 The Deal Mechanics

Artelo is selling a package of "Securities" to investors. Here’s what the investors are buying:

Shares of Common Stock: They are paying $3.45 per share.
Common Warrants: For every share (or prefunded warrant) they buy, they get a warrant to buy two more shares in the future at $3.20 per share. These warrants are good for 5.5 years.
Prefunded Warrants: Some investors might choose these instead of shares. They work like a coupon to buy a share later for just $0.001, helping investors avoid hitting ownership percentage limits.

👉 Why it matters: This structure gives investors immediate stock plus a powerful, long-term option to buy much more stock at a fixed price, which can be very attractive to them.

📊 Price, Dilution & The Math

The numbers tell an important story about cost and impact on existing shareholders.

Total Raised: Up to $11,000,005.
Price Per Share: $3.45.
Immediate Dilution: The company is issuing millions of new shares right now, reducing the ownership percentage of existing shareholders.
Future Dilution (The "Overhang"): The Common Warrants could lead to the issuance of even more shares—up to 200% of the initial purchase. This creates a large potential overhang of shares that could be sold in the future.

👉 Why it matters: While the company gets cash now, the combination of new shares and potential warrant shares can significantly dilute the value for investors who already own the stock.

🔄 Conditions & What Happens Next

The deal isn't final yet. It must "close," which requires several steps:

Closing Date: Will happen once all paperwork is signed and conditions are met.
Key Conditions: The company’s financial statements and legal standing must be accurate, and there can’t been any major negative changes to the business.
Registration Rights: A key part of the deal is that the company must file a registration statement with the SEC to allow these investors to freely resell their shares and warrant shares to the public later. This is a standard requirement in these deals.
Use of Proceeds: The money raised is intended for working capital and general corporate purposes, which for a clinical-stage biotech likely means funding research and operations.

⚖️ Big Picture: Strengths & Risks

This move highlights both the company's strategy and its challenges.

👍 Strength / Positive Signal:
- Access to Capital: Artelo successfully raised $11 million in a tough market for small biotech, which is a vote of confidence from specialized investors.
- Runway Extension: This cash extends the company's financial runway to advance its drug development programs.
⚠️ Risks & Concerns:
- Heavy Dilution: The cost of this capital is high in terms of shareholder dilution, both now and potentially in the future.
- Warrant Overhang: The large number of warrants could put persistent downward pressure on the stock price, as the market anticipates future share issuance.
- Investor Type: These are sophisticated, likely hedge-fund type investors who may sell their shares quickly once they are registered, creating selling pressure.

🧠 The Analogy

Imagine your friend's startup needs money. You give them $100 today for a small slice of the company. As a bonus, they also give you a special coupon (the warrant) that lets you buy two more slices anytime in the next 5 years for just $96 each. The startup gets the cash it needs, but your original slice of the pie just got smaller. And if you (and others) use your coupons later, everyone's original slices get even smaller.

📇 Key Contacts & People

Company: Artelo Biosciences, Inc.
Placement Agent: H.C. Wainwright & Co., LLC
Company Counsel: Bevilacqua PLLC
Investor Counsel: Ellenoff Grossman & Schole LLP (EGS)
Escrow Agent: Continental Stock Transfer & Trust Company
Transfer Agent: Equiniti Trust Company, LLC

🧩 Final Takeaway

Artelo Biosciences raised $11 million by selling shares and attractive warrants to institutional investors. While this provides critical cash for operations, it comes at the cost of significant dilution now and creates a large potential for more dilution later from the warrants, which could weigh on the stock price.

ARTELO BIOSCIENCES, INC. — 8-K Filing